France's Poxel Q3 revenue rises on higher TWYMEEG royalties

By Reuters News


Overview

  • France biopharma reported Q3 2026 revenue up 51% yr/yr, driven by TWYMEEG royalties

  • TWYMEEG net sales in Japan rose 29% yr/yr, triggering higher royalty rate for Poxel

  • Company generated positive net royalties for the first time as royalty rate increased to 10%


Outlook

  • Sumitomo Pharma expects TWYMEEG net sales to exceed JPY 10 bln in FY 2026

  • Upon JPY 10 bln sales milestone, Poxel to receive JPY 1 bln payment from Sumitomo Pharma


Result Drivers

  • TWYMEEG SALES GROWTH - Co said 29% yr/yr increase in TWYMEEG net sales in Japan drove higher royalties

  • ROYALTY RATE INCREASE - Royalty rate on TWYMEEG sales rose from 8% to 10% after sales exceeded JPY 5 bln threshold

  • RETROACTIVE ROYALTY ADJUSTMENT - Q3 revenue included retroactive adjustment to royalties for prior quarter


Company press release:


Key Details

Metric

Beat/Miss

Actual

Consensus Estimate

Q3 Revenue

EUR 1.95 mln


Reuters Recommended Reads

  • Oct 16 - Diagnostics firm Biomerica's Q1 revenue drops on lower clinical lab orders


For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.


(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Capital Com is an execution-only service provider. The present material must be regarded as marketing communication and should not be interpreted as investment research or investment advice. Any opinion that may be provided on this page does not constitute a recommendation by Capital Com or its agents. We do not make any representations or warranty on the accuracy or completeness of the information that is provided on this page. If you rely on the information on this page, then you do so entirely at your own risk